IP Library Granted Patent US 10,323,079
Granted Patent B2
US 10,323,079 · App. 15/928,503 · Granted Jun 18, 2019

Antibody neutralizing human respiratory syncytial virus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,323,079
App. No.
15/928,503
Granted
Jun 18, 2019
Kind
B2
Abstract

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

Claims (10)

1. A method of producing an antibody or antigen binding fragment comprising:

(a) culturing a host cell comprising a polynucleotide encoding an antibody heavy chain variable region and a polynucleotide encoding an antibody light chain variable region under conditions favorable to expression of the polynucleotide; and

(b)recovering the antibody or antigen binding fragment from the host cell and/or culture medium;

wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:7 and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:8.

2. The method of claim 1 , wherein the host cell comprises an expression vector having the polynucleotide encoding the antibody heavy chain variable region and an expression vector having the polynucleotide encoding the antibody light chain variable region.

3. The method of claim 1 , wherein the host cell comprises an expression vector having both the polynucleotide encoding the antibody heavy chain variable region and the polynucleotide encoding the antibody light chain variable region.

4. The method of claim 1 , wherein the host cell is a Pichia cell or a Chinese hamster ovary cell.

5. The method of claim 1 , wherein the polynucleotide encoding the antibody heavy chain variable region encodes an antibody heavy chain comprising the amino acid sequence of SEQ ID NO:23 and the polynucleotide encoding the antibody light chain encodes an antibody light chain comprising the amino acid sequence of SEQ ID NO:25.

6. The method of claim 5 , wherein the polynucleotide encoding the antibody heavy chain comprises the nucleotide sequence set forth in SEQ ID NO:24 and the polynucleotide encoding the antibody light chain comprises the nucleotide sequence set forth in SEQ ID NO:26.

7. The method of claim 1 , wherein the polynucleotide encoding the antibody heavy chain variable region comprises the nucleotide sequence of SEQ ID NO:17 and the polynucleotide encoding the antibody light chain variable region comprises the nucleotide sequence of SEQ ID NO:18.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2018
From: VORA, KALPIT A.; COX, KARA S.; TANG, AIMIN; CHEN, ZHIFENG; DISTEFANO, DANIEL; ZHANG, LAN; SU, HUA-POO
To: MERCK SHARP & DOHME CORP.
Reel/Frame 046402/0786 →